Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
Natera announced a strategic collaboration with TransCode Therapeutics to use the Signatera MRD test to identify MRD-positive colorectal cancer patients for TransCode's Phase 2a trial of TTX-MC138. The trial, run by Quantum Leap Healthcare Collaborative within the PRE-I-SPY program, marks that platform's first expansion beyond breast cancer into colorectal cancer.
Key figures
- Drug Name
- TTX-MC138
- Phase Of Trial
- Phase 2a
- Trial Id
- NCT05868226
- Signatera Publications
- 400+ peer-reviewed publications supporting Natera tests
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.